Abstract
In the 1960s, the platelet inhibitory properties of several drugs were discovered. Like aspirin, they were already in clinical use for other therapeutic indications. Since then, the search for new and more rational antiplatelet strategies has been constant but only moderately successful, although new molecules with high selectivity for platelet function have been developed. The authors briefly review some recent advances in platelet pharmacology and focus their attention on pharmacogenetics, a potential approach to new antiplatelet strategies. Would this approach be successful, individuals rather than epidemiologically defined groups of patients might better benefit from newly targeted antiplatelet drugs.
| Original language | Italian |
|---|---|
| Pages (from-to) | 7-9 |
| Number of pages | 3 |
| Journal | Italian Heart Journal |
| Volume | 2 |
| Issue number | 1 Suppl |
| Publication status | Published - Jan 2001 |
Fingerprint
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Cite this
Nuove strategie antipiastriniche. / de Gaetano, G.; Cerletti, C.
In: Italian Heart Journal, Vol. 2, No. 1 Suppl, 01.2001, p. 7-9.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Nuove strategie antipiastriniche.
AU - de Gaetano, G.
AU - Cerletti, C.
PY - 2001/1
Y1 - 2001/1
N2 - In the 1960s, the platelet inhibitory properties of several drugs were discovered. Like aspirin, they were already in clinical use for other therapeutic indications. Since then, the search for new and more rational antiplatelet strategies has been constant but only moderately successful, although new molecules with high selectivity for platelet function have been developed. The authors briefly review some recent advances in platelet pharmacology and focus their attention on pharmacogenetics, a potential approach to new antiplatelet strategies. Would this approach be successful, individuals rather than epidemiologically defined groups of patients might better benefit from newly targeted antiplatelet drugs.
AB - In the 1960s, the platelet inhibitory properties of several drugs were discovered. Like aspirin, they were already in clinical use for other therapeutic indications. Since then, the search for new and more rational antiplatelet strategies has been constant but only moderately successful, although new molecules with high selectivity for platelet function have been developed. The authors briefly review some recent advances in platelet pharmacology and focus their attention on pharmacogenetics, a potential approach to new antiplatelet strategies. Would this approach be successful, individuals rather than epidemiologically defined groups of patients might better benefit from newly targeted antiplatelet drugs.
UR - http://www.scopus.com/inward/record.url?scp=0035221627&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035221627&partnerID=8YFLogxK
M3 - Articolo
C2 - 11216085
VL - 2
SP - 7
EP - 9
JO - Italian Heart Journal
JF - Italian Heart Journal
SN - 1129-471X
IS - 1 Suppl
ER -